Company Profile For Adolor Corp

Adolor Corp (ADLR.O) (Consolidated Issue listed on NASDAQ Global Market)

sector: Healthcare · industry: Biotechnology ·

As of 8:52pm IST

1.58USD

Price Change

+0.01

Percent Change

+0.64%

Analyst Recommendations

Overview

Adolor Corporation is a biopharmaceutical company. The Company has specialized in the discovery and development of prescription pain management products. It has a number of product candidates in various stages of development, ranging from preclinical studies to pivotal clinical trials. On May 20, 2008, the United States Food and Drug Administration (FDA) approved the Company’s first product, ENTEREG (alvimopan), for the management of postoperative ileus following bowel resection surgery (POI). ENTEREG is specifically indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. The Company in collaboration with Glaxo Group Limited (Glaxo), launched ENTEREG in the United States in mid-2008.

Quick Financial Synopsis

BRIEF: For the nine months ended 30 September 2009, Adolor Corporation's revenues decreased 41% to $24.4M. Net loss totaled $40.9M, up from $14.8M. Revenues reflect a fall in Contract revenues. Higher loss reflects a rise in cost of product sales, an increase in the selling, general & administrative costs, the presence of restructuring charges and a decrease in interest income net due to lower investment balances.